Navigating Systemic Therapy Options in HER2+ Breast Cancer
Panelists discuss a high-level overview of systemic therapies for advanced HER2+ breast cancer, outlining the roles of HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs) in treatment, as well as treatment strategies for patients with brain metastases. They also explore the shared decision-making process that informed the recommendation of the HER2CLIMB regimen.
- Dr Iyengar: Please provide a high-level overview of the systemic therapies that you consider for advanced HER2+ breast cancer. (sSee NCCN Guidelines Version 2.2024.)
- What is the role of HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and ADCs in treating advanced HER2+ breast cancer?
- How do you typically manage treat patients with advanced HER2+ breast cancer and brain metastases?
- Following Dorian’s evaluation, how did the shared decision-making process unfold, and what factors ultimately led you to recommend the HER2CLIMB regimen (trastuzumab [Herceptin] and + tucatinib [Tukysa] and capecitabine [Xeloda])?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
